How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Are there any issues that require special attention in light of NICE’s duties to have due regard to the need to eliminate unlawful discrimination and promote equality and foster good relations between people with a characteristic protected by the equalities legislation and others?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis

Closed for comments This consultation ended on at   Request commenting lead permission

Committee considerations

The evidence

1.7 NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 5 sources, which was discussed by the committee. The evidence included 2 systematic reviews, 2 case series and 1 case report. It is presented in table 2 of the interventional procedures overview. Other relevant literature is in the appendix of the overview.

1.8 The specialist advisers and the committee considered the key efficacy outcomes to be: improved quality of life and prolonged survival.

1.9 The specialist advisers and the committee considered the key safety outcomes to be: peritoneal sclerosis, bowel damage and inadvertent leakage of chemotherapy agents into the environment.

1.10 Patient commentary was sought but none was received.

Committee comments

1.11 The committee noted that the intent of the procedure is palliation.

1.12 There is a potential risk that chemotherapy could be dispersed into the environment, which could be a hazard to operating theatre staff.

1.13 The committee noted that the procedure is usually used with intravenous chemotherapy.

1.14 The committee noted that the technology is evolving to include, for example, using electrostatic charge.

Tom Clutton-Brock
Chair, interventional procedures advisory committee
July 2019